High dose aflibercept may be promising for treatment of age-related macular degeneration
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events ...
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events ...
1. Avacincaptad pegol significantly slowed geographic atrophy over 12 months. 2. Exudative macular neovascularization was comparable among treatment groups. Evidence ...
1. In a phase 2 randomized trial, intravitreal injection with both ranibizumab and OPT-302, a VEGF-C and -D inhibitor, led ...
1. In a large population-based cohort, age-related macular degeneration (AMD) diagnosis was associated with increased risk for depression onset. 2. ...
1. In a systematic review and meta-analysis of observational studies on patients with diabetes, metformin use was associated with a ...
1. In both trials, faricimab was demonstrated to be non-inferior to aflibercept at improving visual acuity in neovascular age-related macular ...
1. There was no added benefit observed with adding lutein and zeaxanthin, omega-3-fatty acids (DHA and EPA), or the combination ...
1. In patients with advanced age-related macular degeneration (AMD) in one eye only or intermediate AMD in either eye, zinc ...
1. Lucentis (ranibizumab) and Avastin (bevaciumab) demonstrated equivalent effects on visual acuity in age-related macular degeneration (AMD) patients after 1 year ...
1. Treatment with human-embryonic stem cell-derived (hESC-derived) retinal pigment epithelium led to improved visual acuity and vision-related quality-of-life measures for ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.